Summary
Regeneron Pharmaceuticals, Inc. reported solid top-line growth in the first quarter of 2026, with total revenues increasing by approximately 19% year-over-year to $3.61 billion. This growth was primarily driven by a substantial increase in collaboration revenue, largely from the Sanofi collaboration, which saw a significant uptick in Dupixent and Kevzara sales. Despite overall revenue growth, net income experienced a decline of approximately 10% to $727.2 million, leading to a decrease in diluted earnings per share to $6.75 from $7.27 in the prior year period. This was influenced by a significant increase in operating expenses, particularly in research and development and cost of goods sold. The company also continued its aggressive share repurchase program and declared a quarterly dividend, indicating a focus on returning value to shareholders. Investors will be closely watching the company's efforts to navigate competitive pressures in key franchises like EYLEA and the ongoing legal matters. Regeneron's balance sheet remains robust, with total assets increasing and a healthy working capital position. The company generated significant cash flow from operations. However, an increase in current liabilities, notably due to a significant finance lease liability, warrants attention. The company also provided updated guidance on expected capital expenditures for the full year 2026, indicating continued investment in infrastructure.
Financial Highlights
46 data points| Revenue | $3.61B |
| R&D Expenses | $1.54B |
| SG&A Expenses | $647.70M |
| Operating Expenses | $2.96B |
| Operating Income | $642.90M |
| Net Income | $727.20M |
| EPS (Basic) | $6.99 |
| EPS (Diluted) | $6.75 |
| Shares Outstanding (Basic) | 104.00M |
| Shares Outstanding (Diluted) | 107.70M |
Key Highlights
- 1Total revenues increased by 19% to $3.61 billion, driven by strong collaboration revenue, mainly from Dupixent and Kevzara.
- 2Net income decreased by 10% to $727.2 million, with diluted EPS falling to $6.75 from $7.27.
- 3Operating expenses rose by approximately 20%, primarily due to higher R&D and cost of goods sold.
- 4EYLEA U.S. net sales declined by 36%, attributed to competitive pressures and the transition to EYLEA HD.
- 5The company repurchased approximately $803.2 million of its common stock during the quarter and announced a new $3.0 billion repurchase program.
- 6Regeneron declared a quarterly cash dividend of $0.94 per share, payable in June 2026.
- 7Cash and cash equivalents decreased by $155.5 million to $2.96 billion, while total marketable securities increased by $304.0 million.